Company intelligence / Profile preview

Kesmalea Therapeutics

London, England, United Kingdomkesmalea.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Kesmalea Therapeutics has not yet reported clinical results; the company remains in the pre-clinical stage, developing a pipeline based on its proprietary SELFTAC® platform to create orally available, CNS penetrant small molecule protein degraders and stabilizers targeting diseases with high unmet need in oncology and neurology.[2][4] No human or animal efficacy data have been published as of May 2025.

Therapeutic areas: OncologyNeurologyOther
Modalities: Small molecules
Industry: Biotech

Partnerships

Syncona Ltd.Oxford Science Enterprises

Beyond the preview

Go deeper on Kesmalea Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kesmalea Therapeutics.

Explore the full profile